Search - tctmd.com

Displaying 41 - 60 of 86

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2020

Caitlin E. Cox

August 28, 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2020

Shelley Wood

July 31, 2020

News Conference News TVT 2020

Antithrombotics After PFO Closure: Much to Discuss, Little Data to Inform

Yael L. Maxwell

June 26, 2020

News Conference News ACC 2020

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

Yael L. Maxwell

March 29, 2020

News Daily News

Bioprosthetic Valve Thrombosis Rare but Not Benign: New Insights

Yael L. Maxwell

February 28, 2020

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2019

Todd Neale

October 31, 2019

News Conference News TCT 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Michael O'Riordan

September 28, 2019

News Conference News TCT 2019

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Shelley Wood

September 19, 2019

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

Todd Neale

September 11, 2019

News Conference News SCAI 2019

Cancer and CV Disease Care: What’s Known? What Lies Ahead for Cardio-Oncology?

Yael L. Maxwell

May 30, 2019

Presentation ARCH 2019

LAA Closure Patient Selection, Imaging and Anti-Thrombotic Therapy

Presenter: Steven J Yakubov

April 11, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for March 2019

Shelley Wood

March 29, 2019

Podcast

DAPT STEMI, MITRAL, Gender Disparities in Trial Design, and More

January 16, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2018

Shelley Wood

October 02, 2018

Presentation TCT 2018

DAPT and Anticoagulation Post TAVR: What is the Standard of Care?

Presenter: Martina Kelly Speight, Patricia Keegan

September 23, 2018

Presentation TCT 2018

Considerations for LAA Closure Devices: FDA Perspective

Presenter: Andrew Farb

September 22, 2018

Presentation TCT 2018

Point to Consider in the Review of the LAAC Related Devices: Japanese Regulatory View: PMDA

Presenter: Akihide Konishi

September 22, 2018

Presentation TCT 2018

The Current Target Population for LAAC Closure Based on the Results of Clinical Trials in Europe

Presenter: Marek Grygier

September 22, 2018

Presentation TCT 2018

The Overview of Clinical Trials and Current Target Population for LAAC Closure

Presenter: Shephal Doshi

September 22, 2018

Advertisement

TCTMD’s Top 10 Most Popular Stories for August 2020

TCTMD’s Top 10 Most Popular Stories for July 2020

Antithrombotics After PFO Closure: Much to Discuss, Little Data to Inform

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

Bioprosthetic Valve Thrombosis Rare but Not Benign: New Insights

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

TCTMD’s Top 10 Most Popular Stories for October 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

Cancer and CV Disease Care: What’s Known? What Lies Ahead for Cardio-Oncology?

LAA Closure Patient Selection, Imaging and Anti-Thrombotic Therapy

TCTMD’s Top 10 Most Popular Stories for March 2019

DAPT STEMI, MITRAL, Gender Disparities in Trial Design, and More

TCTMD’s Top 10 Most Popular Stories for September 2018

DAPT and Anticoagulation Post TAVR: What is the Standard of Care?

Considerations for LAA Closure Devices: FDA Perspective

Point to Consider in the Review of the LAAC Related Devices: Japanese Regulatory View: PMDA

The Current Target Population for LAAC Closure Based on the Results of Clinical Trials in Europe

The Overview of Clinical Trials and Current Target Population for LAAC Closure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content